Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Blockade of oncogenic IB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors

Ceribelli, M and Kelly, PN and Shaffer, AL and Wright, GW and Xiao, W and Yang, Y and Griner, LAM and Guha, R and Shinn, P and Keller, JM and Liu, D and Patel, PR and Ferrer, M and Joshi, S and Nerle, S and Sandy, P and Normant, E and Thomas, CJ and Staudt, LM (2014) Blockade of oncogenic IB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors. Proceedings of the National Academy of Sciences of the United States of America. pp. 11365-11370.

Abstract

In the activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL), NF-B activity is essential for viability of the malignant cells and is sustained by constitutive activity of IB kinase (IKK) in the cytoplasm. Here, we report an unexpected role for the bromodomain and extraterminal domain (BET) proteins BRD2 and BRD4 in maintaining oncogenic IKK activity in ABC DLBCL. IKK activity was reduced by small molecules targeting BET proteins as well as by genetic knockdown of BRD2 and BRD4 expression, thereby inhibiting downstream NF-B-driven transcriptional programs and killing ABC DLBCL cells. Using a high-throughput platform to screen for drug-drug synergy, we observed that the BET inhibitor JQ1 combined favorably with multiple drugs targeting B-cell receptor signaling, one pathway that activates IKK in ABC DLBCL. The BTK kinase inhibitor ibrutinib, which is in clinical development for the treatment of ABC DLBCL, synergized strongly with BET inhibitors in killing ABC DLBCL cells in vitro and in a xenograft mouse model. These findings provide a mechanistic basis for the clinical development of BET protein inhibitors in ABC DLBCL, particularly in combination with other modulators of oncogenic IKK signaling

Item Type: Article
Additional Information: NIBR author: Griner, L institute: NIBR- address only contributor address: (Ceribelli, Kelly, Shaffer, Xiao, Yang, Staudt) Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States (Wright) Biometric Research Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States (Griner, Guha, Shinn, Keller, Liu, Patel, Ferrer, Thomas) Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD 20892, United States (Joshi, Nerle, Sandy, Normant) Constellation Pharmaceuticals, Inc., Cambridge, MA 02142, United States (Griner) Novartis Institutes for BioMedical Research, Inc., Cambridge, MA 02139, United States
Date Deposited: 13 Oct 2015 13:12
Last Modified: 13 Oct 2015 13:12
URI: https://oak.novartis.com/id/eprint/23439

Search

Email Alerts

Register with OAK to receive email alerts for saved searches.